Study of therapeutic effect of ribavirin from infants hospitalized for the respiratory syncytial virus lower divisions of the respiratory tract, as with its attendant diseases, and without them, was launched in 1981 in the control studies ribavirin gave much greater clinical improvement than cure placebo. The treatment has a beneficial effect on such traits as a retraction and bubbling rale, but will not affect the fever and wind. Statistically significant improvement in arterial oxygenation of the child is questionable clinical significance. In one study, a group of children the average value of R02 arterial blood at the beginning of treatment was 49.4 mm RT. Art. and 62.4 mm RT. Art. At the end, that is increased by 13 mm RT. Art. and in the group receiving a placebo, 52-56-4 mm RT. Art. respectively. The impact of treatment on the allocation of the secrets of the virus was different in different stages.
Ribavirin was used as aerosol with a smaller particle size (diameter of the aerosol droplets – 1-2 microns) to reach the lower divisions of the respiratory tract, and performed with the help of oxygen tents on average 3-5 days for 12-20 hours a day. With this method, high concentrations of ribavirin were received in the respiratory secretions with low systemic absorption. In these studies of control not seen any significant intoxication. The impact of aerosol ribavirin was investigated by double-blind method for adult volunteers infected with respiratory syncytial virus. They are in serial pulmonary tests did not reveal the deterioration in the treatment of ribavirin and a month later.